Somaxon Reports Paladin Labs Wins Health Canada Approval of NDS for Silenor
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that its licensee Paladin Labs Inc. has received approval from Health Canada of Paladin's New Drug Submission (NDS) for Silenor^® (doxepin) for the treatment and symptomatic relief of insomnia characterized by frequent nocturnal awakening and/or early morning awakenings.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.